Status:
TERMINATED
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
Lead Sponsor:
University of Kansas Medical Center
Conditions:
Musculoskeletal Cancer
Sarcoma,Soft Tissue
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood tr...
Detailed Description
Resection of bony and soft tissue tumors with endoprosthetic reconstruction often presents a significant risk of perioperative blood loss requiring transfusion. Tranexamic acid (TXA) is an antifibrino...
Eligibility Criteria
Inclusion
- Patients undergoing wide resection of a malignant bony tumor of the lower extremity with endoprosthetic reconstruction.
- Patients undergoing a resection of soft tissue sarcoma measuring \> 5cm.
Exclusion
- Patients undergoing revision endoprosthetic reconstruction
- Patients with known coagulopathy
- Known history of DVT or embolic disease
- Benign tumors
- Patients with allergy to TXA
- Those refusing blood products
- Those concurrently on anti-coagulant therapy
- Pregnant and/or nursing women
- Vulnerable populations as defined by the KUMC IRB
Key Trial Info
Start Date :
January 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2023
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04347122
Start Date
January 28 2020
End Date
August 18 2023
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160